The difference between cystatin C- and creatinine-based eGFR is associated with adverse cardiovascular outcome in patients with chronic kidney disease
The difference between cystatin C- and creatinine-based eGFR is associated with adverse cardiovascular outcome in patients with chronic kidney disease
复制标题
DOI：
10.1016/j.atherosclerosis.2021.08.036
复制
发表时间：
2021-09-24
期刊：
影响因子：
5.3
通讯作者：
Han, Seung Hyeok
中科院分区：
文献类型：
--
作者：
Kim, Hyoungnae;Park, Jung Tak;Han, Seung Hyeok
背景和目的：肾功能下降是心血管疾病（CVD）的重要危险因素。然而，当基于肌酐和胱抑素c的估算肾小球滤过率（eGFR）之间存在差距时，评估心血管疾病的风险可能会很困难。我们研究了慢性肾脏疾病（CKD）患者egfr差异与主要不良心血管事件（MACE）的关系。方法：本前瞻性队列研究基于KDIGO指南（eGFR分类G1: bb0 = 90; g2: 60-89; G3: 30-59; G4: 15-29; G5: = 50/年）对2076例CKD分期患者进行研究（OR, 1.03; 95% CI, 1.01-1.05）。结论：eGFR（creat）和eGFR（cys）之间的显著阳性差异与CKD患者MACE风险升高和CAC进展加快有关。因此，对于eGFR（diff）较高的患者，需要仔细监测CVD。
Background and aims: Decreased kidney function is an important risk factor for cardiovascular disease (CVD). However, assessing risk of CVD may be difficult when there is a gap between creatinine- and cystatin C-based estimated glomerular filtration rate (eGFR). We studied the association of the difference in eGFRs with major adverse cardiovascular events (MACE) in patients with chronic kidney disease (CKD).Methods: This prospective cohort study was conducted in 2076 patients with CKD stages based on the KDIGO guideline (eGFR categories of G1: >= 90; G 2: 60-89; G3: 30-59; G4: 15-29; G5: = 50/year) (OR, 1.03; 95% CI, 1.01-1.05).Conclusions: A large positive difference between eGFR(creat) and eGFR(cys) was associated with a higher risk of MACE and faster CAC progression in patients with CKD. Therefore, careful monitoring of CVD is needed for patients with a higher eGFR(diff).